http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005533009-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 |
| filingDate | 2003-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005533009-A |
| titleOfInvention | Piperazine-substituted arylbenzodiazepines and their use as treatments for psychotic disorders as dopamine receptor antagonists |
| abstract | Described herein is the formula (I): [Chemical 1] As well as salts, solvates and crystalline forms thereof, wherein A is a 5- or 6-membered aromatic ring which may be benzo-fused, having 0 to 3 heteroatoms independently selected from N, O and S; Alk is (C 1-4 ) alkylene which may be substituted with OH, methoxy, ethoxy or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; R 1 is hydrogen or (C 1-4 ) alkyl optionally substituted with OH, OR 3 or OCH 2 CH 2 OH, wherein R 3 is (C 1-2 ) alkyl ); R 2 is H, (C 1-6 ) alkyl, halogen, fluorinated (C 1-6 ) alkyl, OR 4 , SR 4 , NO 2 , CN, COR 4 , CONR 5 R 6 , SO 2 NR 5 R 6 , NR 5 R 6 , NR 5 COR 4 , NR 5 SO 2 R 4 or optionally substituted phenyl (where R 4 is hydrogen, (C 1-6 ) alkyl, fluorinated ( C 1-6 ) alkyl, benzyl or optionally substituted phenyl, and R 5 and R 6 are independently hydrogen, (C 1-6 ) alkyl or optionally substituted phenyl. ); Z is hydrogen, halogen, (C 1-6 ) alkyl, fluorinated (C 1-6 ) alkyl, OR 7 , SR 7 , NO 2 , CN, COR 7 , CONR 8 R 9 , SO 2 NR 8 R 9 , NR 8 SO 2 R 7 , NR 8 R 9 or one or two substituents independently selected from optionally substituted phenyl (where R 7 is hydrogen, (C 1 -6 ) alkyl, fluorinated (C 1-6 ) alkyl, benzyl or optionally substituted phenyl, R 8 and R 9 are independently hydrogen, (C 1-6 ) alkyl or substituted It may be phenyl)]]. Described further, the compounds of formula (I), used as an agent for the treatment of antagonist and psychosis and bipolar disorder of dopamine D 2 receptors, and pharmaceutical formulations of the compounds of formula (I). Further described are compounds useful as intermediates for the synthesis of compounds of formula (I). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007516290-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017222671-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015532645-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019034955-A |
| priorityDate | 2002-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.